Compare Eli Lilly And Co (LLY) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nomura Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,158.75 (market cap $1.02T), while Nomura Holdings Inc trades at $9.82 (market cap $27.46B). The key difference: Eli Lilly And Co is far larger — about 37.1× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| LLY | NMR | |
|---|---|---|
Market Cap | $1.02T | $27.46B |
Sector | Health | Financials |
52-Week High | $1.24K | $10.04 |
52-Week Low | $625.65 | $6.39 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Nomura Holdings (NMR) trades at $9.395, down 0.05% on the day, with a bullish technical signal from moving averages. The company reported record annual net income of $340.74 billion for 2025, with a net income margin of 20.49%, while revenue grew to $1.66 trillion. Recent news highlights strong wholesale revenue momentum and strategic acquisitions, including a U.S. fund management expansion. The stock shows a P/E of 12.78 and P/B of 1.2, indicating potential value relative to earnings.
The outlook for NMR is supported by earnings growth and strategic initiatives, but risks include volatile cash flows and rising debt levels. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism. Further upside depends on sustained profitability and successful integration of recent acquisitions amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
